Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 56 of 116

  1. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  2. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  3. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  4. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  5. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  6. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  7. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  8. JEMPERLI for HPV-negative Head and Neck Squa…

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  9. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  11. JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. JS004

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. JZP598

    Jazz Pharmaceuticals Ireland Limited

    Patients with HER2-expressing solid tumors

    phase 2 small molecule active

    1 trial

  14. JZP598

    Ningbo Cancer Hospital

    Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.

    phase 2 small molecule active

    1 trial

  15. KB707

    Krystal Biotech Netherlands B.V.

    Lung Cancer, Non-small Cell

    phase 2 mab active

    1 trial

  16. KB707

    Krystal Biotech Netherlands B.V.

    Cancer

    phase 2 mab active

    1 trial

  17. KETOROLAC, PREGABALIN

    The George Institute

    Estrogen receptor-positive early breast cancer (ER + BC).

    phase 2 small molecule active

    1 trial

  18. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Vulvar squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

    phase 2 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    Squamous cell carcinoma of vulva/vagina, Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of penis, Squamous cell carcinoma of cervix, Squamous cell carcinoma of anus

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Cardiff Oncology

    Anal cancer

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3)

    phase 2 small molecule active

    1 trial

  25. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  26. KEYTRUDA for Locally recurrent, inoperable…

    Istituto Gentili S.r.l.

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  27. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  28. KL264-01

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  29. KN046

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  30. KN046

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  31. KTE-C19-102

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  32. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  33. Karelizumab combined with etoposide and cisplatin

    Jian Li

    Carcinoma

    phase 2 small molecule active

    1 trial

  34. L2023-K003-002

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  35. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  36. LB101-101

    Centessa Pharmaceuticals plc

    Advanced solid tumors

    phase 2 other active

    1 trial

  37. LB1410

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  38. LBH581

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  39. LBL-007

    BEONE MEDICINES AUS PTY LTD

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  40. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  41. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  42. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  43. LEN+SIN+DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 other active

    1 trial

  44. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  45. LETROZOLE, FULVESTRANT

    Pfizer Australia Pty Ltd

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  46. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    basal cell carcinoma

    phase 2 small molecule active

    1 trial

  47. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Cutaneous squamous cell carcinoma (ccSCC)

    phase 2 small molecule active

    1 trial

  48. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.